DK1353906T3 - Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf - Google Patents
Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte derafInfo
- Publication number
- DK1353906T3 DK1353906T3 DK01273449T DK01273449T DK1353906T3 DK 1353906 T3 DK1353906 T3 DK 1353906T3 DK 01273449 T DK01273449 T DK 01273449T DK 01273449 T DK01273449 T DK 01273449T DK 1353906 T3 DK1353906 T3 DK 1353906T3
- Authority
- DK
- Denmark
- Prior art keywords
- fluorophenethyl
- methanone
- piperazin
- indol
- cyano
- Prior art date
Links
- AQRLDDAFYYAIJP-UHFFFAOYSA-N Pruvanserin Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 AQRLDDAFYYAIJP-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/02—Preparation of lactams
- C07D201/04—Preparation of lactams from or via oximes by Beckmann rearrangement
- C07D201/06—Preparation of lactams from or via oximes by Beckmann rearrangement from ketones by simultaneous oxime formation and rearrangement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10102944A DE10102944A1 (de) | 2001-01-23 | 2001-01-23 | Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1353906T3 true DK1353906T3 (da) | 2004-10-11 |
Family
ID=7671481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01273449T DK1353906T3 (da) | 2001-01-23 | 2001-12-21 | Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7312342B2 (da) |
| EP (1) | EP1353906B1 (da) |
| JP (1) | JP4215195B2 (da) |
| KR (1) | KR100820763B1 (da) |
| CN (1) | CN1213029C (da) |
| AR (1) | AR032261A1 (da) |
| AT (1) | ATE269849T1 (da) |
| AU (1) | AU2002219220B2 (da) |
| BR (1) | BR0116816A (da) |
| CA (1) | CA2435426C (da) |
| CZ (1) | CZ20032202A3 (da) |
| DE (2) | DE10102944A1 (da) |
| DK (1) | DK1353906T3 (da) |
| EC (1) | ECSP034737A (da) |
| ES (1) | ES2223738T3 (da) |
| HU (1) | HUP0401039A3 (da) |
| IL (2) | IL157061A0 (da) |
| MX (1) | MXPA03006534A (da) |
| MY (1) | MY126252A (da) |
| NZ (1) | NZ527779A (da) |
| PL (1) | PL209416B1 (da) |
| PT (1) | PT1353906E (da) |
| RU (1) | RU2295519C2 (da) |
| SK (1) | SK286565B6 (da) |
| TR (1) | TR200402142T4 (da) |
| TW (1) | TW588044B (da) |
| UA (1) | UA74039C2 (da) |
| WO (1) | WO2002059092A1 (da) |
| ZA (1) | ZA200306540B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10246357A1 (de) * | 2002-10-04 | 2004-04-15 | Merck Patent Gmbh | Verwendung von 5-HT2Rezeptorantagonisten |
| DE102004047517A1 (de) | 2004-09-28 | 2006-03-30 | Merck Patent Gmbh | Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid |
| AU2007248282B2 (en) * | 2006-05-05 | 2011-12-08 | Merck Patent Gmbh | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate |
| CN101437793B (zh) * | 2006-05-05 | 2012-08-22 | 默克专利股份有限公司 | 结晶的(3-氰基-1h-吲哚-7-基)-[4-(4-氟苯乙基)哌嗪-1-基]甲酮磷酸盐 |
| CN102816104B (zh) * | 2012-08-30 | 2014-05-21 | 浙江大学 | 一种3-氰基吲哚类化合物的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH421107A (de) * | 1963-06-04 | 1966-09-30 | Sandoz Ag | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |
| CA2084531A1 (en) * | 1991-12-19 | 1993-06-20 | David W. Smith | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines |
-
2001
- 2001-01-23 DE DE10102944A patent/DE10102944A1/de not_active Withdrawn
- 2001-12-21 NZ NZ527779A patent/NZ527779A/xx unknown
- 2001-12-21 PT PT01273449T patent/PT1353906E/pt unknown
- 2001-12-21 MX MXPA03006534A patent/MXPA03006534A/es active IP Right Grant
- 2001-12-21 UA UA2003076931A patent/UA74039C2/uk unknown
- 2001-12-21 BR BR0116816-9A patent/BR0116816A/pt not_active Application Discontinuation
- 2001-12-21 AT AT01273449T patent/ATE269849T1/de active
- 2001-12-21 PL PL364392A patent/PL209416B1/pl not_active IP Right Cessation
- 2001-12-21 RU RU2003124068/04A patent/RU2295519C2/ru not_active IP Right Cessation
- 2001-12-21 JP JP2002559394A patent/JP4215195B2/ja not_active Expired - Fee Related
- 2001-12-21 WO PCT/EP2001/015240 patent/WO2002059092A1/en not_active Ceased
- 2001-12-21 IL IL15706101A patent/IL157061A0/xx unknown
- 2001-12-21 CZ CZ20032202A patent/CZ20032202A3/cs unknown
- 2001-12-21 EP EP01273449A patent/EP1353906B1/en not_active Expired - Lifetime
- 2001-12-21 SK SK1046-2003A patent/SK286565B6/sk not_active IP Right Cessation
- 2001-12-21 CN CNB018221882A patent/CN1213029C/zh not_active Expired - Fee Related
- 2001-12-21 DK DK01273449T patent/DK1353906T3/da active
- 2001-12-21 AU AU2002219220A patent/AU2002219220B2/en not_active Ceased
- 2001-12-21 DE DE60104024T patent/DE60104024T2/de not_active Expired - Lifetime
- 2001-12-21 ES ES01273449T patent/ES2223738T3/es not_active Expired - Lifetime
- 2001-12-21 US US10/466,991 patent/US7312342B2/en not_active Expired - Fee Related
- 2001-12-21 KR KR1020037009645A patent/KR100820763B1/ko not_active Expired - Fee Related
- 2001-12-21 TR TR2004/02142T patent/TR200402142T4/xx unknown
- 2001-12-21 CA CA002435426A patent/CA2435426C/en not_active Expired - Fee Related
- 2001-12-21 HU HU0401039A patent/HUP0401039A3/hu unknown
-
2002
- 2002-01-17 TW TW091100688A patent/TW588044B/zh not_active IP Right Cessation
- 2002-01-18 MY MYPI20020201A patent/MY126252A/en unknown
- 2002-01-23 AR ARP020100222A patent/AR032261A1/es unknown
-
2003
- 2003-07-22 IL IL157061A patent/IL157061A/en not_active IP Right Cessation
- 2003-08-19 EC EC2003004737A patent/ECSP034737A/es unknown
- 2003-08-21 ZA ZA200306540A patent/ZA200306540B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6957A (is) | Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim | |
| DK1383733T3 (da) | Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser | |
| DK1268424T3 (da) | Fremgangsmåde til syntese af perindopril og dets farmaceutisk acceptable salte | |
| DE60217363D1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen | |
| NO20024742L (no) | Heterocykliske forbindelser, deres fremstilling og anvendelse | |
| DK1180518T3 (da) | 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK1185272T3 (da) | Hidtil ukendt anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazin og dets fysiologisk acceptable salte til behandling af bipolære lidelser og mani | |
| NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
| NO20033433L (no) | Fremgangsmåte for fremstilling av 2-(2-pyridylmetyl)sulfinyl- 1H-benzimidasol | |
| DK1279665T3 (da) | Fremgangsmåde til fremstilling af perindopril, analoge forbindelser og salte heraf ved anvendelse af 2,5-dioxo-oxazolidin-mellemforbindelser | |
| IS2475B (is) | Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau | |
| NO20013735D0 (no) | Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner | |
| NO20053809D0 (no) | Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav | |
| DK1353906T3 (da) | Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf | |
| DK1420028T3 (da) | Fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf | |
| NO20035331D0 (no) | Nye heterocyklisk forbindelse og medisinsk anvendelse derav | |
| DK1373232T3 (da) | Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner | |
| DK1265856T3 (da) | Hidtil ukendt fremgangsmåde til fremstillingen af alpha-(2,4-disulfophenyl)-N-tert-butylnitron og farmaceutisk acceptable salte deraf | |
| DK1371659T3 (da) | Fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf | |
| DK1341758T3 (da) | Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme | |
| DK1216253T3 (da) | Fremgangsmåde til fremstilling af methylendiphosphonsyrer og salte deraf | |
| DK1420029T3 (da) | Fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf | |
| NO20033965L (no) | Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse | |
| DE60204791D1 (de) | Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen | |
| DK1293506T3 (da) | Nye 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazin forbindelser, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser |